HEMLIBRA 150MG/ML INJECTION

Yes, HEMLIBRA 150MG/ML INJECTION can be self-administered at home after proper training and instructions from a healthcare professional. However, the decision to self-administer should be made in consultation with the healthcare team.

Yes, HEMLIBRA 150MG/ML INJECTION is approved for use in pediatric patients with hemophilia A. The dosage and administration may vary depending on the age and weight of the child, and it should be prescribed and monitored by a healthcare professional.

HEMLIBRA 150MG/ML INJECTION is specifically designed for the treatment of hemophilia A, which is caused by a deficiency of clotting factor VIII. It is not intended for other types of hemophilia, such as hemophilia B.

HEMLIBRA 150MG/ML INJECTION is administered as a subcutaneous injection. Generally, it is given once a week, every two weeks, or every four weeks, depending on the treatment plan determined by the healthcare provider. The frequency of the administration depends on your disease condition and other factors.

Before you start using HEMLIBRA 150MG/ML INJECTION, talk to your doctor and carefully follow their instructions on when to use a bypassing agent and the dose and schedule you should use. It increases the ability of your blood to clot. Therefore, the dose of bypassing agent required may be lower than the dose you used before starting HEMLIBRA.

Please inform your doctor about all medications you are taking, as HEMLIBRA 150MG/ML INJECTION may interact with other drugs.

This medicine is given as a shot under your skin. It is usually injected into the upper outer arms, thighs, or stomach. Use a different body area each time you give yourself a shot. Keep track of where you give each shot to make sure you rotate body areas. Do not inject into skin areas that are tender, red, bruised, hard, or not intact, or into areas with moles or scars. Use a new needle and syringe each time you inject your medicine. Women should use an effective form of birth control to keep from getting pregnant. Tell your doctor right away if you think you have become pregnant. Your doctor will do lab tests at regular visits to check on the effects of this medicine. Keep all appointments.

The active ingredient in HEMLIBRA 150MG/ML INJECTION is EMICIZUMAB.

HEMLIBRA 150MG/ML INJECTION is primarily prescribed for the treatment of blood disorders, specifically hemophilia A.

HEMLIBRA 150MG/ML INJECTION helps bridge the function of missing clotting factor VIII in people with hemophilia A, helping to reduce bleeding episodes.